胃炎康胶囊辅助治疗胆汁反流性胃炎的效果及安全性

摘要
图/表
参考文献(15)
相关文章 (0)

全文: PDF (0 KB) HTML (38 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨胃炎康胶囊辅助治疗胆汁反流性食管炎的临床效果以及安全性。方法选取2015年5月～2017年5月于我院就诊的120例胆汁反流性胃炎患者作为研究对象，采用动态随机分组法将其分为观察组和对照组，每组各60例。对照组患者给予铝碳酸镁片，观察组患者在对照组基础上给予胃炎康胶囊辅助治疗。观察两组患者的临床疗效，比较两组患者治疗前后的临床症状评分、胃酸分泌量、胃液胆酸、血浆胃动素（MTL）及血清血管活性肠肽（VIP）含量。结果观察组患者的治疗总有效率（96.7%）显著高于对照组（85.0%），差异有统计学意义（P＜0.05）。治疗前，两组患者的症状评分、胃酸分泌量、胃液胆酸、血清VIP及血浆MTL含量比较，差异无统计学意义（P＞0.05）。治疗后，两组患者的症状评分、胃酸分泌量、胃液胆酸、血清VIP含量均显著低于治疗前，差异有统计学意义（P＜0.05），且治疗后观察组患者的上述指标均低于对照组，差异有统计学意义（P＜0.05）。治疗后，两组患者的血浆MTL高于治疗前，差异有统计学意义（P＜0.05），且治疗后观察组患者的血浆MTL显著高于对照组，差异有统计学意义（P＜0.05）。两组患者均未出现药物不良反应。结论胃炎康胶囊辅助治疗胆汁反流性胃炎，能显著提高患者临床治疗有效率，改善各项检查指标，安全性高，值得推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	戴小敏

关键词 ：胃炎康胶囊, 胆汁反流性胃炎, 胃动素, 血管活性肠肽

Abstract：Objective To explore the clinical efficacy and safety of Weiyanang Capsule in the treatment of bile reflux esophagitis.Methods A total of 120 patients with bile reflux gastritis treateed in our hospital from May 2015 to May 2017 were selected as subjects and divided into the observation group and the control group by dynamic random grouping method,60 cases in each group.The control group was treated with Hydrotalcite Tablets,while the observation group was given the auxiliary treatment of Weiyankang Capsule on the basis of the control group.The clinical effects were observed between the two groups.And the clinical symptom scores,gastric acid secretion,astric juice cholic acid content,plasma motilin (MTL)and serum vasoactive intestinal peptide (VIP)before and after treatment were compared between the two groups.Results The total effective rate of the observation group(96.7%)was significantly higher than that in the control group of 85.0%,the difference was statistically significant(P＜0.05).Before treatment,there was no significant difference in symptom score,gastric acid secretion,cholic acid in gastric juice,serum VIP and plasma MTL between the two groups(P＞0.05).The symptom score,gastric acid secretion,gastric acid and serum VIP after treament of two groups were significantly lower than before treatment,the differences were statistically significant(P＜0.05).And after treatment,these indexs of the observation group were lower than those of the control group,the differences were statistically significant(P＜0.05).After treatment,the plasma MTL after treament of two groups were significantly higher than before treatment(P＜0.05),and the plasma MTL in the observation group was significantly higher than that in the control group,the differences were statistically significant(P＜0.05).There were none adverse drug reactions in the two groups.ConclusionWeiyankang Capsule is an effective adjuvant therapy for bile reflux gastritis.It can significantly improve the clinical effective rate,improve various examination indexes,and is highly safe.It is worthy of popularization and application.

Key words： Weiyankang Capsule Bile reflux gastritis Motilin Vasoactive intestinal peptide

基金资助:广东省湛江市科技计划项目（2017B01157）

引用本文:

戴小敏. 胃炎康胶囊辅助治疗胆汁反流性胃炎的效果及安全性[J]. 中国当代医药, 2018, 25(12): 88-91.
DAI Xiao-min. The efficacy and safety of Weiyankang Capsule in the treatment of bile reflux gastritis. 中国当代医药, 2018, 25(12): 88-91.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2018/V25/I12/88

[1]	王玉富.铝碳酸镁联合胃炎康胶囊治疗胆汁反流性胃炎疗效评价[J].中国药业，2017，26（15）：32-34.
[2]	郝建军，苗海军.胃炎康胶囊联合铝碳酸镁治疗胆汁反流性胃炎的临床研究[J].现代药物与临床，2016，31（10）：1542-1546.
[3]	薛萍.中西医结合治疗胆汁反流性胃炎96例[J].中国实验方剂学杂志，2011，22（17）：32-34.
[4]	周利民.铝碳酸镁片联合熊去氧胆酸胶囊治疗胆汁反流性胃炎 168 例[J].中国药业，2013，22（11）：136-137.
[5]	刘翠妮，张瑞芝.多潘立酮与铝碳酸镁联合治疗胆汁反流性胃炎 48 例[J].中国老年学杂志，2016，31（22）：4476-4477.
[6]	姚萍，王磊.原发性胆汁反流性胃炎临床病理特征分析[J].解放军医学杂志，2011，36（5）：498-500.
[7]	易红艳.铝碳酸镁、多潘立酮联合治疗胆汁反流性胃炎的临床研究[J].中国医学创新，2014，7（15）：541-542.
[8]	吴美玉，胡团敏.血管活性肠肽与消化系疾病的研究进展[J].世界华人消化杂志，2012，20（16）：1453-1457.
[9]	王莉.胆汁反流性胃炎78例病因及诊治分析[J].陕西医学杂志，2012，41（4）：457-459.
[10]	肖洪玲，田凌云，方正清，等.半夏泻心汤合并西药治疗胆汁反流性胃炎临床疗效的Meta分析[J].中国临床药理学杂志，2015，31（22）：2257-2259.
[11]	梁莎，罗太梅，陈月莹，等.浅谈“从气”论治胃食管反流病[J].亚太传统医药，2015，11（1）：57.
[12]	许国铭，邹多武，侯晓华，等.多潘立酮临床协作组.多潘立酮及铝碳酸镁治疗胆汁反流性胃炎多中心临床观察[J].中华消化杂志，2013，23（5）：275-278.
[13]	官小莉，汪晖.胃食管反流病患者生存质量测评量表的研究进展[J].中华护理杂志 2015，50（1）：97-101.
[14]	庄瑞斐，顾庆华.胆胃宁颗粒剂治疗胆胃不和型胆汁反流性胃炎临床疗效观察[J].时珍国医国药，2016，27（12）：2940-2943.
[15]	高瑞梅，许琳，孟欣颖，等.原发性胆汁反流性胃炎胃黏膜胃动素、血管活性肠肽的表达[J].世界华人消化杂志，2010，18（7）：722-725.